Source:http://linkedlifedata.com/resource/pubmed/id/19657776
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
2009-8-24
|
pubmed:abstractText |
Autoimmune fatigue syndrome (AIFS) is characterized by chronic nonspecific complaints, consistently positive antinuclear antibodies (ANA), and lack of alternate medical explanations. A newly recognized antibody, named anti-Sa, was detected in approximately 40% of the patients by Western blot (WB) using HeLa extract. Some patients with AIFS later develop chronic fatigue syndrome (CFS), and most of them are positive for anti-Sa. On the other hand, Muro et al. reported anti-DFS70 in patients with CFS. Anti-Sa and anti-DFS70 were turned out to be same specificities by exchanging studies of blind sera. The target antigen of anti-DFS70 was identified as lens epithelium derived growth factor/transcription co-activator p75 (LEDGF/p75). The objectives of this study are to confirm whether the target antigen of anti-Sa is also LEDGF/p75, and to develop ELISA system by using recombinant protein. Recombinant protein of LEDGF/p75 was purchased from Protein One (Bethesda, MD, USA). We developed an ELISA system to detect anti-LEDGF/p75 by coating this recombinant protein. 226 sera of AIFS patients (including 36 CFS patients) were applied to this ELISA assay and Western immunoblot, and it was revealed that anti-Sa-positive sera defined by WB and sera positive for anti-LEDGF/p75 on ELISA were identical. Moreover, reactivities of anti-Sa on WB were inhibited by pre-incubating with recombinant LEDGF/p75, and eluted antibodies from the nitrocellulose membrane could react on the ELISA. These results confirm that the Sa antigen is LEDGF/p75. The ELISA assay using recombinant LEDGF/p75 could be a promising tool for measuring anti-Sa and consequently for diagnosing CFS.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Antinuclear,
http://linkedlifedata.com/resource/pubmed/chemical/Autoantibodies,
http://linkedlifedata.com/resource/pubmed/chemical/Intercellular Signaling Peptides...,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/lens epithelium-derived growth...
|
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
1607-842X
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
42
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
492-6
|
pubmed:meshHeading |
pubmed-meshheading:19657776-Antibodies, Antinuclear,
pubmed-meshheading:19657776-Autoantibodies,
pubmed-meshheading:19657776-Autoimmune Diseases,
pubmed-meshheading:19657776-Blotting, Western,
pubmed-meshheading:19657776-Child,
pubmed-meshheading:19657776-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:19657776-Fatigue Syndrome, Chronic,
pubmed-meshheading:19657776-HeLa Cells,
pubmed-meshheading:19657776-Humans,
pubmed-meshheading:19657776-Intercellular Signaling Peptides and Proteins,
pubmed-meshheading:19657776-Recombinant Proteins
|
pubmed:year |
2009
|
pubmed:articleTitle |
Autoantibodies to lens epithelium-derived growth factor/transcription co-activator P75 (LEDGF/P75) in children with chronic nonspecific complaints and with positive antinuclear antibodies.
|
pubmed:affiliation |
Department of Pediatrics, Nippon Medical School, Bunkyo City, Tokyo, Japan.
|
pubmed:publicationType |
Journal Article,
Evaluation Studies
|